Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
Completed · Phase 3 · NCT04903626
Conditions: Hepatitis C Virus (HCV)
At a glance
- Research payments reported, 2025
- $52,327
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 286
About the trial
- Sponsor
- AbbVie
- Tested
- Glecaprevir/Pibrentasvir (GLE/PIB) (drug)
- Dates
- Started 2021-08-24; completion 2024-09-17
- Results posted
- Yes
HCV infection is a global health problem. HCV mainly affects liver cells and causes the liver to become inflamed and damaged. This study will evaluate how safe and effective glecaprevir/pibrentasvir (GLE/PIB) is in adult and adolescent participants with acute HCV infection. GLE/PIB is an approved drug for the treatment of chronic HCV. Around 283 participants at least 12 years of age with acute HCV Infection will be enrolled in approximately 70 sites worldwide. Participants will receive oral tablets of GLE/PIB once daily (QD) for 8 weeks and will be followed for 12 weeks after the end of treatment. There may be higher treatment burden for participants in this trial compared to their standa…
From ClinicalTrials.gov, last updated 2025-04-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $52,327 in research payments for this study in 2025 (9 payments).
Products named: Mavyret
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mona-gekanju Toeque, M.D.,MPH Infectious Disease · Los Angeles, CA
- Yanely Pineiro Puebla, M.D. Internal Medicine · Pembroke Pines, FL
- Stuart C. Gordon, M.D. Gastroenterology · Detroit, MI
- Alireza Farabi, MD Infectious Disease · Las Vegas, NV
- Robert S. Brown JR., MD Hepatology · New York, NY
- Jonathan M. Fenkel, MD Gastroenterology · Philadelphia, PA
- John H. Smith, M.D. Gastroenterology · Norfolk, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cornell University Weill Medical College $16,908
- Gastrointestinal & Liver Specialists of Tidewater PLLC DBA Digestive & Liver Disease Specialists $13,161
- Angels Clinical Research Institute Inc $11,250
- Thomas Jefferson University $5,034
- Las Vegas Research Center $3,700
- Henry Ford Health Hospital, MI $2,125
- Aids Healthcare Foundation $150
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.